ReNerve – Commencement of Trade as ReNerve Limited Looks to Progress Product Portfolio

Highlights:
• ReNerve Limited to commence trading on the ASX at 12:00pm (AEDT) today (26 November 2024) under
the ticker “RNV”, following its successful IPO of 35m shares at $0.20 per share.
• Funds from the listing will be used to progress the Company’s portfolio of peripheral nerve injury (PNI)
repair products to market, and to accelerate its US and global commercial expansion. ReNerve’s existing
NervAlign® Nerve Cuff product already has FDA approval, and is currently in use in the US surgical
market.
• The global nerve repair market opportunity is currently valued at over US$1.6 billion per year and is
estimated to be worth US$6.19 billion per year by 2031; driven by increased adoption of biologic
products in the treatment of PNI.
• Company management boasts strong foundations in research-driven medical innovations, and a proven
track record of bringing new products to market.
• ReNerve possesses a long growth runway thanks to early-mover advantage, proven technology, and a
comprehensive range of products in development.